Brind.

AI Sleep Analysis Platform Seeks FDA Clearance for US Market Entry

1 report, 1 independent Updated Sep 1

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

HoneyNaps is expanding the commercialization of SOMNUM Clinical, its AI-powered clinical trial analytics service. The service automatically analyzes polysomnography data and currently holds two clearances from the U.S. Food and Drug Administration. The platform applies scoring criteria from the American Academy of Sleep Medicine (AASM) to minimize variability across study sites.

From sleepreviewmag.com

Why it matters

Some supportBrind's analysis of the reports

The company is also registered as a contract research organization with the Korea National Enterprise for Clinical Trials. This service supports global pharmaceutical, medical device, and digital health companies by providing standardized sleep analysis services for clinical trials.

From sleepreviewmag.com

Who's involved

FDAThe U.S. Food and Drug Administration is the body from which the company seeks market entry clearance.
American Academy of Sleep MedicineThe American Academy of Sleep Medicine provides the scoring criteria adopted by the platform.

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
American Academy of Sleep Medicine
American professional society for sleep clinicians and researchers

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sep 1sleepreviewmag.com